GSK to Buy Tesaro, Developer of Niraparib.
GlaxoSmithKline (GSK) has announced plans to buy Waltham, MA-based biotech Tesaro, maker of the once-daily oral PARP inhibitor niraparib (Zejula), in a deal valued at $5.1 billion.